La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Novo Nordisk Gestione

Gestione criteri di controllo 3/4

Novo Nordisk's Il CEO è Lars Jorgensen, nominato in Jan2017, ha un mandato di 7.58 anni. possiede direttamente 0.002% delle azioni della società, per un valore di $ 12.45M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.5 anni e 6.4 anni.

Informazioni chiave

Lars Jorgensen

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	7.6yrs
Proprietà del CEO	0.002%
Durata media del management	3.5yrs
Durata media del Consiglio di amministrazione	6.4yrs

Aggiornamenti recenti sulla gestione

Nessun aggiornamento

Recent updates

Novo Nordisk: Great Value Buying Opportunity, Thanks To The Much-Needed Rotation

Aug 18

Novo Nordisk: SOTP After Impressive FY23 And Weight Loss Going Mainstream, Maintain Buy

Feb 23

Novo Nordisk: Irrational Exuberance Isn't Worth The Risk

Feb 16

Novo Nordisk: Outlook For Weight Loss Drugs In 2024

Jan 22

Taking Novo Nordisk To The Next Level

Jan 15

Profiting From Obesity Drugs HRTS, Novo Nordisk And Eli Lilly

Jan 02

Novo Nordisk: Latest Insights Confirm Exceptionally Bullish Opportunity

Dec 12

Novo Nordisk: Eli Lilly's Zepbound Approval Is Not A Threat To Valuation

Nov 24

Novo Nordisk: Growing To Potentially Become The First Trillion-Dollar European Champion

Oct 24

Novo Nordisk: Catching The Falling Knife Now Could Really Hurt

Sep 22

Novo Nordisk: Strong Fundamentals Meet Technical Uptrends

Aug 30

Novo Nordisk: Denmark's Coca-Cola

Jul 25

The Case For Novo Nordisk: Growth, Dividends, And A New Treatment Frontier

Jul 11

Novo Nordisk Is A Hold Despite Explosive Growth In Diabetes And Obesity Care

Jun 23

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Lars Jorgensen rispetto agli utili di Novo Nordisk?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	DKK 90b
Mar 31 2024	n/a	n/a	DKK 89b
Dec 31 2023	n/a	n/a	DKK 84b
Sep 30 2023	n/a	n/a	DKK 75b
Jun 30 2023	n/a	n/a	DKK 67b
Mar 31 2023	n/a	n/a	DKK 61b
Dec 31 2022	DKK 60m	DKK 17m	DKK 56b
Sep 30 2022	n/a	n/a	DKK 53b
Jun 30 2022	n/a	n/a	DKK 51b
Mar 31 2022	n/a	n/a	DKK 49b
Dec 31 2021	DKK 58m	DKK 17m	DKK 48b
Sep 30 2021	n/a	n/a	DKK 46b
Jun 30 2021	n/a	n/a	DKK 44b
Mar 31 2021	n/a	n/a	DKK 43b
Dec 31 2020	DKK 57m	DKK 14m	DKK 42b
Sep 30 2020	n/a	n/a	DKK 42b
Jun 30 2020	n/a	n/a	DKK 41b
Mar 31 2020	n/a	n/a	DKK 40b
Dec 31 2019	DKK 55m	DKK 14m	DKK 39b
Sep 30 2019	n/a	n/a	DKK 39b
Jun 30 2019	n/a	n/a	DKK 38b
Mar 31 2019	n/a	n/a	DKK 38b
Dec 31 2018	DKK 41m	DKK 11m	DKK 39b
Sep 30 2018	n/a	n/a	DKK 38b
Jun 30 2018	n/a	n/a	DKK 39b
Mar 31 2018	n/a	n/a	DKK 39b
Dec 31 2017	DKK 32m	DKK 9m	DKK 38b

Compensazione vs Mercato: Dati insufficienti per stabilire se la retribuzione totale di Lars sia ragionevole rispetto ad aziende di dimensioni simili nel mercato US.

Compensazione vs guadagni: La retribuzione di Lars è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Lars Jorgensen (58 yo)

7.6yrs

Mandato

DKK 60,100,000

Compensazione

Mr. Lars Fruergaard Jorgensen serves as Director at Danmarks Nationalbank since April 2024. He has been Chief Executive Officer and President of Novo Nordisk A/S since January 2017and serves as its Member...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Lars Jorgensen	President	7.6yrs	DKK 60.10m	0.0021% DKK 12.7m
Karsten Knudsen	Executive VP	6.5yrs	DKK 21.50m	0.000010% DKK 60.8k
Henrik Wulff	Executive VP of Product Supply	no data	DKK 22.00m	0.000060% DKK 365.0k
Camilla Sylvest	Executive VP of Commercial Strategy & Corporate Affairs and Member of the Management Board	no data	DKK 21.30m	Nessun dato
Martin Lange	Executive VP of Development & Member of the Management Board	3.6yrs	DKK 20.90m	Nessun dato
Marcus Schindler	EVP of Research & Early Development	3.4yrs	DKK 20.90m	Nessun dato
Maziar Doustdar	Executive VP of International Operations & Member of the Management Board	no data	Nessun dato	0.0011% DKK 6.9m
Douglas Langa	Executive VP of North America Operations & Member of Management Board	no data	Nessun dato	Nessun dato
Ludovic Helfgott	Executive VP	no data	Nessun dato	Nessun dato
Tania Sabroe	Executive VP of Global People & Organisation and Member of Management Board	1.4yrs	Nessun dato	Nessun dato
David Moore	Executive VP of Corporate Development & Member of Management Board	1.4yrs	Nessun dato	Nessun dato
Jacob Martin Rode	Head of Investor Relations	no data	Nessun dato	Nessun dato

3.5yrs

Durata media

54yo

Età media

Gestione esperta: Il team dirigenziale di NVO è considerato esperto (durata media dell'incarico 3.5 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Sylvie Gregoire	Independent Director	9.4yrs	DKK 1.80m	Nessun dato
Helge Lund	Independent Chairman of the Board	7.4yrs	DKK 3.10m	Nessun dato
Henrik Poulsen	Vice Chairman of the Board	3.4yrs	DKK 2.00m	Nessun dato
Laurence Debroux	Independent Director	5.4yrs	DKK 2.00m	Nessun dato
Martin MacKay	Independent Director	6.4yrs	DKK 1.70m	Nessun dato
Andreas Fibig	Independent Director	6.4yrs	DKK 1.40m	Nessun dato
Kasim Kutay	Non-Independent Director	7.4yrs	DKK 1.20m	Nessun dato
Christina Law	Independent Director	2.4yrs	DKK 1.30m	Nessun dato
Liselotte Hyveled	Employee Representative Director	2.4yrs	DKK 800.00k	0% DKK 0
Mette Jensen	Employee Non-Independent Representative Director	6.4yrs	DKK 1.20m	Nessun dato
Thomas Rantzau	Employee Representative Non-Independent Director	6.6yrs	DKK 1.00m	Nessun dato
Elisabeth Christensen	Employee Representative Director	2.4yrs	DKK 800.00k	Nessun dato

6.4yrs

Durata media

58.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di NVO sono considerati esperti (durata media dell'incarico 6.4 anni).

Novo Nordisk Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Recent updates

Novo Nordisk: Great Value Buying Opportunity, Thanks To The Much-Needed Rotation

Novo Nordisk A/S Decides to Pay Interim Dividend for 2024, Payable on 19 August 2024 for A and B Shares and 26 August 2024 for ADRs

Novo Nordisk: Growth Only Limited By Manufacturing Capacity

Novo Nordisk A/S Provides Earnings Guidance for the Year 2024

Novo Nordisk: Better Buying Opportunities Ahead

European Regulatory Authority Adopts A Positive Opinion for an Update of the Wegovy® Label to Reflect Risk Reduction of Major Adverse Cardiovascular Events

Novo Nordisk Receives Complete Response Letter in the US for Once-Weekly Basal Insulin Icodec

Novo Nordisk: Buy On Dips

Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy

Novo Nordisk: Leading The Fight Against Diabetes And Obesity

Novo Nordisk: Considerable Growth Beyond Ozempic

The FTC Cracks Down On Novo Nordisk's Ozempic

Novo Nordisk Announces Wegovy (Semaglutide Injection) Available in Canada

Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy

Novo Nordisk: The Moat Won't Last Forever

Mankind Reportedly Joins Race for Healthium Medtech

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Cardior Pharmaceuticals GmbH from EQT Life Sciences and others for €1.03 billion.

Novo Nordisk Announces Awiqli Recommends for Approval for the Treatment of Diabetes by the European Regulatory Authorities

Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront

Novo Nordisk Announces US Food and Drug Administration Approves Wegovy® Based on A Supplemental New Drug Application for the Indication of Reducing Risk of Major Dose Cardiovascular Events

Novo Nordisk: My 'Hold' Thesis For 2024 - The Premium Must Be Justified

Novo Nordisk, A Very Healthy Pharma Stalwart

Novo Nordisk: SOTP After Impressive FY23 And Weight Loss Going Mainstream, Maintain Buy

Novo Nordisk: Irrational Exuberance Isn't Worth The Risk

Novo Nordisk A/S Proposes Final Dividend for the Year 2023

Novo Nordisk A/S (CPSE:NOVO B) announces an Equity Buyback for DKK 20,000 million worth of its shares.

Novo Nordisk: Outlook For Weight Loss Drugs In 2024

Taking Novo Nordisk To The Next Level

Novo Nordisk A/S Announces Topline Results from the Combine 3 Phase 3A Trial of Once-Weekly IcoSema

Profiting From Obesity Drugs HRTS, Novo Nordisk And Eli Lilly

Novo Nordisk: Latest Insights Confirm Exceptionally Bullish Opportunity

Novo Nordisk: Eli Lilly's Zepbound Approval Is Not A Threat To Valuation

Novo Nordisk A/S to Report First Half, 2024 Results on Aug 07, 2024

Novo Nordisk: Growing To Potentially Become The First Trillion-Dollar European Champion

Novo Nordisk Revises Earnings Guidance for the Year 2023

Novo Nordisk to Stop the Once-Weekly Injectable Semaglutide Kidney Outcomes Trial, Flow, Based on Interim Analysis

Novo Nordisk: Catching The Falling Knife Now Could Really Hurt

Novo Nordisk A/S (CPSE:NOVO B) acquired Embark Biotech ApS for approximately €470 million.

Novo Nordisk: Strong Fundamentals Meet Technical Uptrends

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Inversago Pharma Inc. from Genesys Capital Partners Inc., Accel-Rx, Tarnagulla Ventures Pty. Ltd., Fonds de solidarité FTQ, adMare BioInnovations and others for $1 billion.

Novo Nordisk A/S Provides Earnings Guidance for the Year 2023

Novo Nordisk: Denmark's Coca-Cola

The Case For Novo Nordisk: Growth, Dividends, And A New Treatment Frontier

Novo Nordisk Is A Hold Despite Explosive Growth In Diabetes And Obesity Care

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire a 64.4% stake in Biocorp Production (ENXTPA:ALCOR) for €99.1 million.

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media